Almirall, S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carlos Gallardo Piqué
- Full Time Employees
- 2,026
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Ronda Del General Miter, 151 Barcelona Spain 08022
- IPO Date
- Aug 3, 2012
- Website
- almirall.com
- Similar Companies
- Business
- Almirall, S.A. is a global biopharmaceutical company headquartered in Barcelona, Spain, primarily engaged in the research, development, and commercialization of medicines focused on medical dermatology. Its core products and services include biologic therapies for dermatological diseases such as psoriasis, atopic dermatitis, actinic keratosis, and acne. Key products in its portfolio include Ilumetri® (tildrakizumab), a biologic treatment for psoriasis; Ebglyss® (lebrikizumab), a monoclonal antibody for autoimmune dermatological conditions; Wynzora®, a topical cream combining calcipotriene and betamethasone dipropionate for mild to moderate psoriasis; and Klisyri®, a topical therapy for actinic keratosis. The company emphasizes innovation through its extensive R&D pipeline, including novel targets such as IL-1RAP for autoimmune diseases, and invests heavily in developing advanced therapies for dermatological indications across European and select international markets. Recent significant changes include sustained double-digit sales growth driven by the biologics portfolio with Ilumetri® and Ebglyss® achieving substantial year-over-year net sales increases, reflecting strong commercial execution especially in Europe. Almirall expanded its market presence through new launches and geographic extensions of its dermatology products, notably increasing the footprint of Ebglyss® across 10 European countries. The company advanced its pipeline and discovery efforts via strategic partnerships, including a collaboration with Microsoft to integrate generative artificial intelligence (AI) to accelerate drug discovery and optimize data management. Additionally, it entered a drug discovery agreement with Absci, an AI-driven biotech firm, marking its first de novo AI drug discovery collaboration aimed at enhancing therapeutic development for chronic dermatological diseases. Almirall also pursued portfolio expansion through the acquisition of a U.S. dermatology product portfolio and strengthened commercialization alliances to support future growth. Operationally, the company reported a 12.8% net sales increase and a 27.1% EBITDA growth in the first nine months of 2025, reaffirming its leadership position in medical dermatology. Founded in 1944, Almirall operates principally in Europe, targeting dermatologists and healthcare professionals with a focus on specialty pharmaceuticals in the dermatology segment. It leverages partnerships with biotechnology and pharmaceutical companies to reinforce its R&D capabilities and market reach. The company maintains a strong commitment to innovation, patient-centric solutions, and expanding access to its dermatology treatments globally while continuing to invest in early-stage research to sustain long-term value creation. Almirall’s geographic operations span mainly European countries with strategic expansion efforts underway in the United States and China, especially for key products like Klisyri® and efinaconazole. Its positioning as a medical dermatology leader is supported by a diversified product portfolio, ongoing pipeline advancement, and strategic alliances emphasizing cutting-edge technologies such as AI-assisted drug development. Overall, Almirall is a well-established pharmaceutical company specializing in dermatology therapies, undergoing dynamic growth through new product launches, enhanced R&D capabilities with AI integration, strategic acquisitions, and expanded commercial operations across Europe and beyond.
Almirall, S.A. (ALMRY) Q1 2026 Earnings Call Transcript
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
Almirall, S.A. (LBTSF) Q4 2025 Earnings Call Transcript
Almirall, S.A. (LBTSF) Presents at 44th Annual J.P.
Almirall, S.A. (LBTSF) Q3 2025 Earnings Call Transcript
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Almiralll, S.A. (LBTSF) Q2 2025 Earnings Call Transcript
Almiralll, S.A. (LBTSF) Q1 2025 Earnings Call Transcript
Almiralll, S.A. (LBTSF) Q4 2024 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q3 2024 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q1 2024 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q4 2023 Earnings Call Transcript
Almirall, S.A. (LBTSF) Q3 2023 Earnings Call Transcript
Digital Leaders from Almirall and Merck KGaA, Darmstadt, Germany to Keynote Veeva Summit Online, Europe